Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis

Laboratory Investigation

Volumn 76, Issue 1, 1997, Pages 37-51

  Magi Galluzzi, C ^a   Mishra, R ^a   Fiorentino, M ^d   Montironi, R ^c   Yao, H ^b   Capodieci, P ^a   Wishnow, K ^a   Kaplan, I ^a   Stork, P J S ^b   Loda, M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d Deaconess Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIAGNOSIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; RESTRICTION FRAGMENT;

APOPTOSIS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL CYCLE PROTEINS; CELL DIVISION; GENE EXPRESSION; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASE; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0031036906     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Aihara M, Truong L, Dunn J, Wheeler T, Scardino P, and Thompson T (1994). Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25:797-801.
2. Alessi DR, Gomez N, Moorhead G, Lewis T, Keyse SM, and Cohen P (1995). Inactivation of p42 MAP Kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL 100, in various cell lines. Curr Biol 5:283-295.
3. Alessi DR, Smith R, and Keyse SM (1993). The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts. Oncogene 8:2015-2020.
4. Blenis J (1993). Signal transduction via the MAP kinases: Proceed at your own RSK. Proc Natl Acad Sci USA 90:5889-5892.
5. Bokemeyer D, Sorokin A, Yan M, Ahn NG, Templeton DJ, and Dunn MJ (1996). Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts. J Biol Chem 271:639-642.
6. Bradford MM (1976). A rapid and sensitive method for the quantisation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Cano E and Mahadevan LC (1995). Parallel signal processing among mammalian MAP Kinases. Trends Biochem Sci 20: 117-22.
8. Charles CH, Abler AS, and Lau LC (1992). cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene 7:187-190.
9. Chu Y, Solski PA, Khosravi-Far R, Der CJ, and Kelly K (1996). The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271:6497-6501.
10. Colombel MC and Buttyan R (1995). Hormonal control of apoptosis: The rat prostate gland as a model system. Methods Cell Biol 46:369-85.
11. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, and Buttyan R (1993). Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400.
12. Cowley S, Paterson H, Kemp P, and Marshall C (1994). Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells. Cell 77:841-852.
13. Day ML, Zhao X, Wu S, Swanson PE, and Humprey PA (1994). Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. Cell Growth Differ 5:735-741.
14. Derijard B, Hibi M, Wu I-H, Barrett T, Su B, Deng T, Karin M, and Davis RJ (1994). JNK 1: A protein kinase stimulated by UV light and Ha-ras that binds and phosphorylates the c-jun activation domain. Cell 76:1025-1037.
15. Dewey WC, Ling CC, and Meyn RE (1995). Radiation-induced apoptosis: Relevance to radiotherapy. Int J Radiat Oncol Biol Phys 33:781-796.
16. Egawa S, Kadmon D, and Miller GJ (1992). Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinogen 5:52-61.
17. Estus S, Zakds WJ, Freeman RS, Gruda M, Bravo R, and Johnson EM (1994). Altered gene expression in neurons during programmed cell death: Identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 127:1717-1727.
18. Fleming WH, Hamel A, and MacDonald R (1986). Expression of c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46:1535-1538.
19. Franklin CC and Kraft AS (1995). Constitutively active MAP kinase kinase (MEK!) stimulates SAP kinase and c-jun transcriptional activity in U937 human leukemic cells. Oncogene 11:2365-2374.
20. Furuya Y and Issacs JT (1993). Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 133:2660-2666.
21. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, and Beach D (1995). cdc25 phosphatases as potential oncogenes. Science 269:1575-1577.
22. cdc2 Cell 67:197-211.
23. Gavrieli Y, Sherman Y, and Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501.
24. Gleason DF and the Veterans Administartion Cooperative Urological Research Group (1977). Histopathologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: The prostate. Philadelphia: Lea and Febinger, 171-198.
25. Guan K, Broyles SS, and Dixon JE (1991). A Tyr/Ser protein phosphatase encoded by vaccinia virus. Nature 350:359-362.
26. Guan KL, Hakes DJ, Wang Y, Park HD, Cooper TG, and Dixon JE (1992). A yeast protein phosphatase related to the vaccina virus VH1 phosphatase is induced by nitrogen starvation. Proc Natl Acad Sci USA 89:12175-12179.
27. Gupta SK, Gallego C, and Johnson GL (1992). Mitogenic pathways regulated by G protein oncogenes. Mol Biol Cell 3:123-128.
28. Ham J, Babji C, Whitfield J, Pfarr DM, Lallemand D, Yaniv M, and Rubin LL (1995). A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14:927-939.
29. Hill CS and Treisman R (1995). Transcriptional regulation by extracellular signals: Mechanisms and specificity. Cell 80: 199-211.
30. Hockenbery D (1995). Defining apoptosis. Am J Pathol 146: 16-19.
31. Hockenbery DM, Zutter M, Hickey W, Nahm M, and Korsmeyer SJ (1991). Bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965.
32. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, and Ewing CM (1994). Genetic alterations in prostate cancer. Cold Spring Harb Symp Quant Biol 59:653-659.
33. Isaacs JT, Furuya Y, and Berges R (1994). The role of androgen in the regulation of programmed cell death/ apoptosis in normal and malignant prostatic tissue. Cancer Biol 5:391-400.
34. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, and Woodgett JR (1994). The stress-activated protein kinase subfamily of c-jun kinases. Nature 369:156-160.
35. Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, and Johnson GL (1993). A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 260:315-319.
36. Leav I, Magi Galluzzi C, Ziar J, Stork PJS, Ho SM, and Loda M (1996). Mitogen-activared protein kinase and mitogen-activated kinase phosophatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest 75:361-370.
37. Leavers SJ and Marshall CJ (1992). MAPKAP kinase-2: A novel protein kinase activated by mitogen-activated protein kinase. EMBO J 11:569-574.
38. Liu Y, Gorospe M, Yang C, and Holbrook N (1995). Role of mitogenic activated protein kinase phosphatase during the cellular response to genotoxic stress. J Biol Chem 270:8377-8380.
39. Loda M, Fogt F, French FS, Posner M, Cukor B, Aretz HT, and Alsaigh N (1994a) Androgen receptor immunohistochemistry on paraffin-embedded tissue. Mod Pathol 7:388-391.
40. Loda M, Lipman J, Cukor B, Bur M, Kwan P, and DeLellis R (1994b). Nodular foci in parathyroid adenomas and hyperplasias: An immunohistochemical analysis of proliferative activity. Hum Pathol 25:1050-1056.
41. Maddy SQ, Chrisholm GD, Busutti L, and Habib FK (1989). Epidermal growth factor receptors in human prostate cancer: Correlation with histological differentiation of the tumor. Br J Cancer 60:41-44.
42. Magi-Galluzzi C and Loda M (1996). Molecular events in the early phases of prostate carcinogenesis. Eur Urol 30:167-176.
43. Magi-Galluzzi C, Montironi R, Giannulis I, Diamanti L, Scarpelli M, Muzzonigro G, and Polito M (1993). Prostatic invasive adenocarcinoma: Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Pathol Res Pract 189:1154-1160.
44. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, and Campbell ML (1992). Expression of protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944.
45. McNemar Q (1947). Note on the sampling error of the difference between correlate proportions or percentages. Psychometrica 12:153-157.
46. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, and Karin M (1994). Selective activation of the jnk signaling cascade and c-jun transcriptional activity by the small GTPases rac and cdc42Hs. Science 266:1719-1723.
47. Misra-Press A, Rim CS, Yao H, Roberson MS, and Stork PJS (1995). A novel MAP Kinase phosphatase: Structure, expression and regulation. J Biol Chem 270:14587-14596.
48. Montironi R, Magi-Galluzzi C, and Fabris G (1995). Apoptotic bodies in prostate intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 191:873-800.
49. Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, and Fabris G (1994a). Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate, prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Clin Pathol 47:906-913.
50. Montironi R, Magi-Galluzzi C, Scarpelli M, and Diamanti L (1994b). Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem 19(Suppl):238-245.
51. Noguchi T, Metz R, Chen L, Mattei MG, Carrasco D, and Bravo R (1993). Structure, mapping and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of erp on cell growth. Mol Cell Biol 13:5195-5205.
52. Peehl DM, Wehner N, and Stamey TA (1987). Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 10:281-289.
53. Potter M (1972). Immunoglobulin-producing tumors and myeloma proteins of mice. Phys Rev 52:613-719.
54. Robinson D, He F, Pretlow T, and Kung H-J (1996). A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 93:5958-5962.
55. Ruderman JV (1993). MAP kinase and the activation of quiescent cells. Curr Opin Cell Biol 5:207-213.
56. Sikes RA and Chung LW (1992). Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 52:3174-3181.
57. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, and Press MF (1989). Studies of the HER-2neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
58. Sluss HK, Barett T, Derijard B, and Davis RJ (1994). Signal transduction by tumor necrosis factor mediated by JNK protein kinases. Mol Cell Biol 14:8376-8384.
59. Stein D, Wu J, Fuqua SAW, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buch berg AM, Osborne CK, and Margolis B (1994). The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 13:1331-1340.
60. Steiner MS (1995). Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 153:1085-1096.
61. Sun H, Charles CH, Lau LF, and Tonks NK (1993). MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75:487-493.
62. Sun H, Tonks NK, and Bar-Sagi D (1994). Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science 266:285-288.
63. Thompson CB (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462.
64. Thompson TC, Southgate J, Kitchners G, and Land H (1989). Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917-930.
65. Turkeri LN, Sakr WA, Wykes SM, Grignon DJ, Pontes JE, and Macoska JA (1994). Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 25:199-205.
66. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, and Kolesnick RN (1996). Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75-79.
67. Wu J, Lau LF, and Sturgill TW (1994). Rapid deactivation of MAP kinase in pc12 cells occurs independently of induction of phosphatase MKP-1. FEBS Lett 353:912.
68. Xia Z, Dickens M, Raingeaud J, Davis RJ, and Greenberg ME (1995). Opposing effect of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331.
69. Yao H, Labudda K, Rim C, Capodieci P, Loda M, and Stork PJS (1995). Cyclic adenosine monophosphate can convert epidermal growth factor into a differentiating factor in neuronal cells. J Biol Chem 270:1-6.
70. Zheng CF and Guan KL (1993). Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, mek1 and mek2. J Biol Chem 268:16116-16119.
71. Zinck R, Cahill MA, Kracht M, Sachsenmaier C, Hipskind RA, and Nordheim A (1995). Protein synthesis inhibitors reveal differential regulation of mitogen-activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1. Mol Cell Biol 15:4930-4938.
72. Zincke H (1990). Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Semin Urol 8:175-183.